Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
19 stopped studies mapped to Malignant Brain Stem Neoplasm and descendants · 100% state a reason
Over the 19 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06639607 | PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and…(PRiME II) | Phase 1 / Phase 2 | suspended | Oct 15, 2024 | Washington University School of Medicine | Drugs/Equipment Unavailable | Other (stated, no rule matched) |
| NCT03396575 | Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy…(BRAVO) | Phase 1 | terminated | Jan 11, 2018 | University of Florida | Not feasible to accrue due to competing studies | Enrollment / accrual |
| NCT02742883 | A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG) | Phase 2 | suspended | Apr 19, 2016 | Burzynski Research Institute | Clinical Hold | Other (stated, no rule matched) |
| NCT03330197 | A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including… | Phase 1 / Phase 2 | terminated | Nov 6, 2017 | Alaunos Therapeutics | Sponsor decision due to slow accrual | Enrollment / accrual |
| NCT04239092 | 9-ING-41 in Pediatric Patients With Refractory Malignancies. | Phase 1 | terminated | Jan 23, 2020 | Actuate Therapeutics Inc. | The decision to conclude study was made to optimize the clinical study design and protocol to… | Safety / toxicity |
| NCT04804709 | Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive… | Phase 1 | terminated | Mar 18, 2021 | Columbia University | FDA withdrew approval of the new drug application (NDA) for panobinostat as of March 24, 2022… | Sponsor / business decision |
| NCT03690869 | REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System… | Phase 1 / Phase 2 | terminated | Oct 1, 2018 | Regeneron Pharmaceuticals | Sponsor Decision | Sponsor / business decision |
| NCT03416530 | ONC201 in Pediatric H3 K27M Gliomas | Phase 1 | terminated | Jan 31, 2018 | Jazz Pharmaceuticals | The Sponsor terminated the study to prioritize enrollment in a randomized Phase 3 trial of ONC201… | Safety / toxicity |
| NCT04771897 | A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma…(KONQUER) | Phase 1 | terminated | Feb 25, 2021 | Bexion Pharmaceuticals, Inc. | Bexion Pharmaceuticals has decided to close the BXQ-350.AD study to enrollment prior to the… | Enrollment / accrual |
| NCT05123534 | A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in… | Phase 2 | suspended | Nov 17, 2021 | SonALAsense, Inc. | The study is suspended due to lack of funding but not due to safety concerns. | Safety / toxicity |
| NCT04341311 | Phase I Study of Marizomib + Panobinostat for Children With DIPG(DIPG) | Phase 1 | terminated | Apr 10, 2020 | Dana-Farber Cancer Institute | Withdrawal of support from BMS | Other (stated, no rule matched) |
| NCT05063357 | 131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse… | Phase 1 | withdrawn | Oct 1, 2021 | Y-mAbs Therapeutics | Corporate business decision. Not due to safety or efficacy concerns. | Safety / toxicity |
| NCT01884740 | Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial… | Phase 1 / Phase 2 | terminated | Jun 24, 2013 | Weill Medical College of Cornell University | The study was prematurely closed in December 2021 due to low accrual. | Enrollment / accrual |
| NCT02758366 | Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse… | Phase 2 | terminated | May 2, 2016 | Meyer Children's Hospital IRCCS | Study was terminated due to high heterogeneity of enrolled patients | Enrollment / accrual |
| NCT02607124 | A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy | Phase 1 / Phase 2 | terminated | Nov 17, 2015 | Children's Hospital Medical Center, Cincinnati | A competing trial was opened for patient population with combination of ribociclib and everolimus. | Other (stated, no rule matched) |
| NCT01400672 | Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma | Phase 1 | terminated | Jul 22, 2011 | Masonic Cancer Center, University of Minnesota | Treatment ineffective; Extreme toxicity | Safety / toxicity |
| NCT04051047 | Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma | Early Phase 1 | withdrawn | Aug 9, 2019 | University of Michigan Rogel Cancer Center | Withdrawn by Principal Investigator | Investigator |
| NCT01182350 | Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) | Phase 2 | terminated | Aug 16, 2010 | Karen D. Wright MD | Per design: Stop if fewer than 3 cohorts by molecular classification were with 10 participants or… | Enrollment / accrual |
| NCT03632317 | A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With… | Phase 2 | withdrawn | Aug 15, 2018 | University of Michigan Rogel Cancer Center | low accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 19 days agoSource updated Sep 11, 2026source: clinicaltrials